Research Articles

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region

The recombinant dengue virus type-4 vaccine candidate 2AA30 was attenuated in rhesus monkeys due to an engineered 30-nucleotide deletion in the 3'-untranslated region of the viral genome. A clinical trial to evaluate the safety and immunogenicity of a single dose of 2Adelta30 was conducted with 20 adult human volunteers. The vaccine candidate was well tolerated and did not cause systemic illness in any of the 20 volunteers. Viremia was detectable in 14 volunteers at a mean level of 1.6 log10 plaque-forming units/ml of serum, although all 20 volunteers seroconverted with a seven-fold or greater increase in serum neutralizing antibody titer on day 28 post-vaccination (mean titer = 1:580). A mild, asymptomatic, macular rash developed in 10 volunteers, and a transient elevation in the serum level of alanine aminotransferase was noted in five volunteers. The low level of reactogenicity and high degree of immunogenicity of this vaccine candidate warrant its further evaluation and its use to create chimeric vaccine viruses expressing the structural genes of dengue virus types 1, 2, and 3.

This article has been cited by other articles:

				A. A. Kraus, W. Messer, L. B. Haymore, and A. M. de Silva Comparison of Plaque- and Flow Cytometry-Based Methods for Measuring Dengue Virus Neutralization J. Clin. Microbiol., November 1, 2007; 45(11): 3777 - 3780. [Abstract] [Full Text] [PDF]

				L. J. White, M. M. Parsons, A. C. Whitmore, B. M. Williams, A. de Silva, and R. E. Johnston An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice J. Virol., October 1, 2007; 81(19): 10329 - 10339. [Abstract] [Full Text] [PDF]

				G. S. Park, K. L. Morris, R. G. Hallett, M. E. Bloom, and S. M. Best Identification of Residues Critical for the Interferon Antagonist Function of Langat Virus NS5 Reveals a Role for the RNA-Dependent RNA Polymerase Domain J. Virol., July 1, 2007; 81(13): 6936 - 6946. [Abstract] [Full Text] [PDF]

				T. A. Romero, E. Tumban, J. Jun, W. B. Lott, and K. A. Hanley Secondary structure of dengue virus type 4 3' untranslated region: impact of deletion and substitution mutations. J. Gen. Virol., November 1, 2006; 87(Pt 11): 3291 - 3296. [Abstract] [Full Text] [PDF]

				Y. Zhou, M. P. Mammen Jr, C. Klungthong, P. Chinnawirotpisan, D. W. Vaughn, S. Nimmannitya, S. Kalayanarooj, E. C. Holmes, and C. Zhang Comparative analysis reveals no consistent association between the secondary structure of the 3'-untranslated region of dengue viruses and disease syndrome J. Gen. Virol., September 1, 2006; 87(9): 2595 - 2603. [Abstract] [Full Text] [PDF]

				J. E. Blaney Jr., J. M. Matro, B. R. Murphy, and S. S. Whitehead Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys J. Virol., May 1, 2005; 79(9): 5516 - 5528. [Abstract] [Full Text] [PDF]

				J. E. Bryant, P. F. C. Vasconcelos, R. C. A. Rijnbrand, J. P. Mutebi, S. Higgs, and A. D. T. Barrett Size Heterogeneity in the 3' Noncoding Region of South American Isolates of Yellow Fever Virus J. Virol., March 15, 2005; 79(6): 3807 - 3821. [Abstract] [Full Text] [PDF]

				J. E. BLANEY JR., C. T. HANSON, C.-Y. FIRESTONE, K. A. HANLEY, B. R. MURPHY, and S. S. WHITEHEAD GENETICALLY MODIFIED, LIVE ATTENUATED DENGUE VIRUS TYPE 3 VACCINE CANDIDATES Am J Trop Med Hyg, December 1, 2004; 71(6): 811 - 821. [Abstract] [Full Text] [PDF]

				F. Guirakhoo, Z. Zhang, G. Myers, B. W. Johnson, K. Pugachev, R. Nichols, N. Brown, I. Levenbook, K. Draper, S. Cyrek, et al. A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys J. Virol., September 15, 2004; 78(18): 9998 - 10008. [Abstract] [Full Text] [PDF]

				R. Men, T. Yamashiro, A. P. Goncalvez, C. Wernly, D. J. Schofield, S. U. Emerson, R. H. Purcell, and C.-J. Lai Identification of Chimpanzee Fab Fragments by Repertoire Cloning and Production of a Full-Length Humanized Immunoglobulin G1 Antibody That Is Highly Efficient for Neutralization of Dengue Type 4 Virus J. Virol., May 1, 2004; 78(9): 4665 - 4674. [Abstract] [Full Text] [PDF]

				F. Guirakhoo, K. Pugachev, Z. Zhang, G. Myers, I. Levenbook, K. Draper, J. Lang, S. Ocran, F. Mitchell, M. Parsons, et al. Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates J. Virol., May 1, 2004; 78(9): 4761 - 4775. [Abstract] [Full Text] [PDF]

				B. W. JOHNSON, T. V. CHAMBERS, M. B. CRABTREE, F. GUIRAKHOO, T. P. MONATH, and B. R. MILLER ANALYSIS OF THE REPLICATION KINETICS OF THE CHIMERIVAXTM-DEN 1, 2, 3, 4 TETRAVALENT VIRUS MIXTURE IN AEDES AEGYPTI BY REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION Am J Trop Med Hyg, January 1, 2004; 70(1): 89 - 97. [Abstract] [Full Text] [PDF]

				S. Jaiswal, N. Khanna, and S. Swaminathan Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2 J. Virol., December 1, 2003; 77(23): 12907 - 12913. [Abstract] [Full Text] [PDF]

				C. Y.-H. Huang, S. Butrapet, K. R. Tsuchiya, N. Bhamarapravati, D. J. Gubler, and R. M. Kinney Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development J. Virol., November 1, 2003; 77(21): 11436 - 11447. [Abstract] [Full Text] [PDF]

				S. S. Whitehead, B. Falgout, K. A. Hanley, J. E. Blaney Jr., L. Markoff, and B. R. Murphy A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys J. Virol., December 20, 2002; 77(2): 1653 - 1657. [Abstract] [Full Text] [PDF]

				A. G. Pletnev, R. Putnak, J. Speicher, E. J. Wagar, and D. W. Vaughn From the Cover: West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy PNAS, March 5, 2002; 99(5): 3036 - 3041. [Abstract] [Full Text] [PDF]

				K. A. Hanley, J. J. Lee, J. E. Blaney Jr, B. R. Murphy, and S. S. Whitehead Paired Charge-to-Alanine Mutagenesis of Dengue Virus Type 4 NS5 Generates Mutants with Temperature-Sensitive, Host Range, and Mouse Attenuation Phenotypes J. Virol., January 15, 2002; 76(2): 525 - 531. [Abstract] [Full Text] [PDF]